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Abstract: Target therapy is the result of many years research dedicated to identify the characteristics of cancer cells 
and confirmation the differences between cancer cells and normal cells. The treatment of cancer is focused on 
killing the fast dividing cells. The need to achieve specificity in the treatment of cancer has led to designing and 
synthesizing of high selective agents, like monoclonal antibodies. To choose the right monoclonal antibody, first is 
important to identify the antigen on the surface of tumor cells. Monoclonal antibody-based therapy is one of the 
most successful therapeutic approaches for solid tumors and malignancies. Antibodies have shown high complexity 
in the manner of action and their biological properties. Manipulation of genes of antibodies with microbiologic 
techniques has led to significant modification in murine proteins. In order to not be recognized by human immune 
system, murine antibodies can be transduced to human or humanized monoclonal antibodies. Various studies have 
shown the ability of the antibodies to target the specific tumors and localize in or around the tumor cells. 
Identification of specific antigen on the surface of the tumor cells provides the formulation of monoclonal antibodies 
from animals and humans, which selectively bind to antigen and allows less toxicity to healthy cells. Conjugation of 
antibodies with cytotoxic drugs, toxins and radioisotopes provides development of selective and specific reagents. 
This immunoconjugates have three parts: monoclonal antibody selective for specific antigen, molecule that has a 
capacity to kill the cancer cell, and linker that connect the antibody and the active molecule. Antibody-drug 
conjugates, have chemotherapy drugs attached to the antibody, target the surface of cancer cells and deliver the toxic 
substance to that specific area. This approach can eliminate some of the side effects of chemotherapy, which can 
damage healthy cells when used as a single agent. Novel processes of enzymatically conjugating small molecule 
toxins to antibodies allow formulation of high selectivity agents. Radioimmunotherapy is a treatment that uses 
monoclonal antibodies in combination with radiation. By attaching a monoclonal antibody to a radioactive molecule, 
this technique can deliver a dose of radiation therapy directly to tumor cells. The aim of this paper is to do a review 
of literature for most commonly used antibodies and radioimmunoconjugates in the treatment of different types of 
cancer showing in the same time our contribution with obtaining results. 
Keywords: monoclonal antibodies, immunoconjugates, cancer.  
 
1. INTRODUCTION 
The use of monoclonal antibodies (MAbs) is a well-known type of targeted anticancer therapy. A typical strategy for 
the treatment of cancer is focused on targeting and killing fast dividing cells. This approach requires to achieve high 
target specificity and, as a result, has led to designing and synthesizing a number of highly selective monoclonal 
antibodies. Selective targeted therapy allows imparting less toxicity to healthy cells, thus causing insignificant side 
effects [1,2].   
A monoclonal antibody is a laboratory-produced protein that is engineered to atach a specific cancer cells. The 
progress of genetic engieering over the years has provided many opportunities for design and production of four 
main categories of monoclonal antibodies (pure murine, chimeric, humanized and pure human). The suffix of the 
drug name is: -momab (murine), -ximab (chimeric), -zumab (humanized) and mumab (human) [6].   
1.1. Commonly used anticancer monoclonal antibodies  
Several anti-cancer monoclonal antibodies are available for human usage in registered formulations and depending 
on the percentage of participation of human and animal fragments, the approved anticancer antibodies can be 
grouped into three categories [6]: 
1.1.1. Naked murine monoclonal antibodies were first used antibodies, but they showed two major disadvantages. 
Derived from rodents they are recognized by the human immune system developing human anti-murine antibodies 
(HAMA). HAMA inactivate and eliminate the murine antibodies and generate allergic reactions and anaphylactic 
shock, result of antibody-HAMA complex. Murine Fc fragment provides a resticted binding to effector cells and 
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activation of inderect pathways CDC and ADCC. To overcome this problems and to minimize immunogenicity, the 
murine antibody was engineered and were obtained antibodies similar to human antibodies, providing better 
phramacological response [3]. 
1.1.2. Chimeric IgG1 antibodies, produced by cloning of recombinant DNA contain the genes of variable region of 
the murine antibody and the genes of the constant region of human antibodies. These antibodies have over 65% of 
the human parts and less immugenicity in comparison with a pure murine antibodies and include following 
representatives: 
Rituximab is the first registered antibody, since November 1997. It's an anti-CD20 antibody and it works through 
direct induction of apoptosis and indirectly through ADCC and CDC. Is obtained by genetic engineering and 
composed from immunoglobulin constant region of human IgG1 and variable regions from the murine anti-CD20 
antibody 2B8. Rituximab was approved for treatment of NHL (non-Hodgkin lymphoma) and CLL (chronic 
lymphocytic leukemia) [7]. Many studies have proven the clinical efficiency of rituximab arthritis in combination 
with methotrexate fot treatment of rheumatoid arthritis [8].  
Cetuximab, younger chimeric antibody, produced ftom the anti-EGFR murine antibody 225 and the human IgG1 
antibody. Cetuximab has almost the same affinity for the EGFR, as the primary murine antibody. It works against 
over-expressed EGFR via ADCC and is used in treatment of colorectal cancer [9], non-small cell lung cancer [10] 
and in combination with conventional radiotherapy is active for squamous-cell carcinoma of the head and neck [11]. 
1.1.3. Humanized IgG1 antibodies contains more than 90% of human protein sequences and are obtained by 
transplanting the CDR of the murine antibody in a human antibody. Because they have only 5-10% of mrine 
proteins have shown the lowest immunogenicity. The most used antibodies are following: 
Trastuzumab is a first approved humanized antibody as a potent anti-HER2/neu antibody, originate from murine 
4D5 antibody. By composition is a protein of 1328 amino acids and has a molecular weight of 148 kDa. The original 
murine antibody 4D5 inhibits the proliferation of cell lines that have overexpressed HER2 receptors. Like a potent 
inhibitor of the growth of human breast cancer cells 4D5 was chosen for further clinical development. To reduce the 
probability of generation of HAMA, a murine monoclonal antibody (4D5) was humanized. The new humanized 4D5 
have improved clinical efficacy by reducing its immunogenicity and Fc region who support ADCC. This antibody 
has a higher affinity for the antigen (HER2/neu) binding than 4D5, approximately Kd = 0.1nM. Is registered for the 
treatment of breast cancer with overexpressed HER2/neu. Trastuzumab is binding to the IV subdomain of the 
receptor and manifests the effect through ADCC (Fc region contains carbohydrate residues that interact with other 
parts of the immune system  effector cells) [12]. Many clinical trials were shown the efficacy of trastuzumab in 
other types of cancer with overespressed HER2/neu, like prostate, ovarian and non-small cell lung cancer [13-15].   
Alemtuzumab is anti-CD52 antibody and is used in CLL therapy (chronic lymphocytic leukemia) and T cell 
lymphoma. It works throught direct induction of apoptosis and indirectly through ADCC and CDC [16]. Except in 
the treatment of leukemia alemtuzumab is promising drug in therapy of multiple sclerosis [17] and like an 
immunosuppressant in bone marrow and kidney transplantation [18].  
Bevacizumab is a humanized monoclonal antibody that was obtained from a murine anti-VEGF antibody A.4.6.1. 
and human IgG1. VEGF (vascular epidermal growth factor) is an important growth factor that regulate process of 
angiogenesis and in the case of metastases has overexpression of this receptor [19]. In 2004, is approved for 
treatment of metastatic colorectal cancer. Two years latet, in combination with FOLFOX4 (5-fluorouracil, 
leucovorin and oxaliplatin) is approved as a secondary therapy of metastatic colorectal cancer [20].  
1.1.4. Human antibodies contain fully human amino acid sequence derived antibody region therapeutics where 
antigen specificity has been selected either in vivo by the use of genetically modified mice or by antibody 
engineering processes combined with screening. 
Panitumumab is a first fully human monoclonal antibody used in therapy since 2006. Represent a IgG2 antibody 
and was generated by XenoMouse techology. [21]. Scheider-Merck et al. [22] described the mechanism of action of 
panitumumab in cells of myeloid lineage. Panitumumab can recruiting ADCC by neutrophils and monocytes, but 
can not recruiting NK cell-mediated ADCC. It is active in KRAS metastatic colorectal cancer. The studies was 
shown that this antibody significantly prolonged the life of a patients compared with conventional chemotherapy 
[22].  
The secound fully human antibody Ofatumumab is a human anti-CD20 IgG1 antibody with the mechanism of 
action is through CDC and ADCC, but it doesn't activate direct apoptoss. In higher degree promotes CDC than 
ADCC and is used in various forms of leukemia (non-Hodkin's lymphoma, chronic lymphocytic leukemia, B-cell 
lymphoma) [23] and is also active in most autoimmune diseases (multiple sclerosis, rheumatoid arthritis) [24, 25].  
Ipilimumab is a fully human IgG1 monoclonal antibody generated from unique transgenic mouse (HuMab), when 
the endogenous murine immunoglobulin genes have been repleaced with human loci. It is anti CLTA-4 (cytotoxic 
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T-lymphocyte-associated protein 4) antibody registered in 2011 for treatment of metastatic melanoma [26]. It works 
by binding CTLA-4, excliding inhibitory mechanism and allows destroying of tumor cells. The clinical trials have 
shown that this antibody alone or in combination with radiotherapy is active in prostate cancer [27] and in 
combination with paclitaxel and carboplastin is active in non-small cell and small cell lung cancer [28, 29]. 
Nivolumab is a youngest IgG4 monoclonal antobody registered in 2014 for therapy of metastatic melanoma. This 
antibody was generated by imunization of transgenic mice. It works by blocking the PD-1 (programmed death-1), 
which is an inhibitory receptor expressed on the surface if T cells [30]. The clinical trials have shown that 
nivolumab is active in non-small cell lung cancer and is registered for the therapy of this type of cancer [31]. 
Fully human and humanized antibodies carry a lower risk for inducing immune responses in humans than mouse or 
chimeric antibodies.  
Monoclonal antibodies can be used as naked  unconjugated or conjugated with different types of drugs, toxins and 
radioisotopes, in order to improve the specificity and pharmacological response and to reduce the side effects [35]. 
1.2.  Immunoconjugates 
Conjugation of antibodies provides development of cancer-specific cytotoxic reagents. Each of these conjugates 
carrying their therapeutic capacity and intrinsic toxicity [32]. The drug conjugates have the potential advantage due 
to the higher drug release in tumor cells and reducing the drug resistance. The immunotoxins are very interesting for 
examinations because of their high specific activity [33], while the radio-labeled antibodies beside the therapeutic 
have the potential for molecular imaging [34]. Each immunoconjgate has an enhanced therapeutic specificity due to 
the conjugation with antibody which shows specificity to a particular antigen on the surface of tumor cells [32].  
1.2.1. Radioimmunoconjugates 
The high selectivity and specificity of monoclonal antibodies (mAbs) are usually exploited for the production of a 
variety of immunoconjugates where the antibody is linked either to cytotoxic drugs and toxins or to radioisotopes. 
Each of these conjugates carries its own therapeutic cargo and, therefore, exhibits an intrinsic toxicity [3]. Drug 
immunoconjugates have the potential advantage over the free drug substance of enhancing drug delivery to tumor 
cells with a concomitant reduction of drug resistance. Immunotoxins are very interesting tools for investigation 
because of their high specific biological activity [4], whereas radiolabeled antibodies have the additional advantage 
that can be used also for molecular imaging and therapy [5]. 
Significant radiopharmaceuticals based on immunoconjugates for diagnostic and therapeutical purpose used 
different radioisotopes (68Ga, 177Lu, 90Y, 131/124/123I, 99mTc/188Re). Several studies have shown that already existing 
radiolabeled formulations, using beta and alpha emitters (90Y, 131I, 177Lu, 188Re, 227Th, 225Ac) are potent therapy 
against many cancers. Many radioimmunoconjugates employing techniques of positron emission tomography (PET) 
and single photon emission tomography (SPECT) for imaging are used for diagnosis, follow the efficacy of the 
treatment and planning radiotherapy. 
Until now, a series of clinical and preclinical trials of cancer imaging and therapy with radioimmunoconjugates has 
been carried out [36-38]. Many efforts have been devoted to obtain stable antibody conjugates with different 
radioisotopes and suitable chelators, while preserving the native  
Full length mAbs and mAb fragments offer an excellent approach for creating high-affinity, labeling imaging 
preparation because of (1) the high specificity for targets, (2) an abundance of reactive amino acid residues (i.e., 
lysines and cysteines) for conjugation of chelators, (3) the plethora of therapeutic mAbs on the market and within 
clinical trials, (4) the clinical acceptance of radioimmunoscintigraphy, and (5) the versatility of imaging agent design 
offered by mAb engineering. 
The chelator allows binding to the antibody on the one side and coordinative binding of radioisotpes on the other 
side. The most commonly used chelators are: DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), 
DTPA (diethylene triamine pentaacetic acid), TCMC (1,4,7,10-tetra-(2-carbamoyl methyl)-cyclododecane), HYNIC 
(succinimidyl-6-hydrazino-nicotinamide) and DTPA derivates. Radioimmutherapeutics used in the treatment of 
lymphoma are more advanced than any other agents. The only two approved RIT, tositumomab-131I (approved 2003) 
and ibritumomab tiuksetin-111In or 90Y (approved 2002), are anti-CD20 and are indicated for the treatment of B-cell 
lymphoma. Tositumomab-131I is a murine IgG2a monoclonal antibody labeled with iodine-131 and commercially is 
used for treatment of NHL and B-cell lymphoma. Ibritumomab tiuxetin kit contains murine IgG antibody and 
chelator tiuxetin (modified DTPA) which can be tagged with 111In (for imaging) and 90Y (for therapy) [34].  
It was done a lot of efforts to formulate other stable immunoconjugates for therapy of different lymphomas and 
other types of cancer. 
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2. OUR CONTRIBUTION AND FUTURE REASEARCH  
Over last 6 our group is involved in the several projects related to formulation of stable antibody conjugates in a 
form of freeze-dried (ready to use cold kit) for labeling with suitable radioisotope for therapy (90Y, 177Lu), including 
preclinical investigations as a step forward to the clinical studies [36-38]. 
To avoid problems related to the stability and transport of antibodies, technology of freeze-drying was introduced 
that can be applied as well for radiolabeled antibodies (Figure 1). 
 
Figure 1. Freeze-drying technology for producing immunoconjugates 
 
In our previous work we already indicated the possibi
preparation of cold kit freeze-dried formulation of conjugated antibody (rituximab, trastuzumab) and peptide-based 
radiopharmaceuticals for labeling with with 90Y and 177Lu [36-38]. 
We developed two freeze-dried trastuzumab conjugates using bifunctional chelators (BFC) - DOTA  (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid), DTPA DTPA (diethylene triamine pentaacetic acid),  and DTPA 
derivative 1B4M-DTPA[IB4M-DTPA=2-(4-isothiocyanatobenzyl)-6-methyl-diethylene-triaminepentaacetic acid], 
as the most widely investigated for a successful labeling of antibodies with metallic radionuclides [14]. Schematic 
drawings of the chemical structures of these BFCs are illustrated in Figure 2. 
  
Figure 2. Chemical structure of the bifunctional chelators employed in this study 
Radiolabeling was realized by combining the BFC-derivatized antibody with the appropriate radioisotope.  
Several techniques have been used to characterize the stability of the antibody in the formulated immunoconjugates. 
A protein integrity and purity were accessed by Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-
PAGE). Vibrational (infrared and Raman) spectroscopy provided molecular structure information and was found 
convenient for verification of possible changes in the secondary structure. The number of chelating groups per one 
trastuzumab molecule was obtained by MALDI-TOF-MS. Quality control and stability were examined by ITLC 
using different mobile phases. 
All our obtained results shows successful formulation of stable radioimmunoconjugates which makes this proposed 
freeze-dried kit as potential radiopharmaceutical in vivo investigations and possibility to introduce this e technology 
for preparation of freeze-dried formulation  of conjugated antibody using different chelators for labeling with Zr-89, 
positron emitter (half-life of 78.4 h) compatible with the time needed to achieve optimal tumor-to-non tumor ratios 
(typically 2 4 days for intact monoclonal antibody). 
 
3. CONCLUSION 
The use of monoclonal antibodies in anti-cancer therapy is one of the big successes of the past decade. The success 
is based on long scientific researches in order to understand the complexity of the antibodies, target antigens, 
antibody-antigens functions and immune regulation of tumor growth. The affinity of the antibodies can be modified 
and adjusted to inhibit binding to normal tissues and to improve the penetration and retention in tumor tissue. The 
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selectivity toward cancer cells can be increased by modification of size, valence, structure and specificity of the 
antibodies. Improved conjugation technology allows the development of immunoconjugates and selective delivering 
of cytotoxic agents to tumor cells. These immunoconjugates are considered as next generation of anticancer 
antibodies. The progress of radiopharmacy provides development of radioimmunoconjugates which are more 
effective than immunotherapy with pure antibodies. 
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